It highlights the potential of combination treatment of CML employing specific BCR–ABL tyrosine kinase targeting and provides a rationale for the design of future conditioning protocols for stem cell transplantation in CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.